Table 1 Patient’s characteristics at inclusion and during ICU stay
Variable | Overall population (n = 129) | Alive at ICU discharge (n = 85) | Deceased at ICU discharge (n = 44) | p value |
|---|---|---|---|---|
Age (yr) | 69 [59–77] | 63 [58–73] | 77 [68–82] | < 0.001 |
Sex male | 94 (73%) | 56 (66%) | 38 (86%) | < 0.01 |
BMI (kg m−2) | 28 [25–31] | 28 [25–31] | 28 [25–32] | NS |
Immunosuppression | 9 (7%) | 4 (5%) | 5 (11%) | NS |
Time between 1st symptoms and ICU admission (day) | 8 [6–11] | 9 [6–12] | 7 [5–10] | NS |
Time between 1st RT-PCR and ICU admission (day) | 1 [0–4] | 1 [0–4] | 1 [0–2] | NS |
SAPS2 | 39 [32–52] | 36 [28–46] | 49 [39–53] | < 0.001 |
SOFA score at ICU admission | 4 [2–7] | 4 [2–6] | 5 [3–8] | < 0.05 |
ARDS criteria | 87 (67%) | 51 (60%) | 34 (81%) | < 0.05 |
Respiratory support | < 0.01 | |||
 Oxygen or NIV or HFNO only | 42 (33%) | 35 (41%) | 7 (17%) | |
 IV at any time | 87 (67%) | 50 (59%) | 34 (83%) | |
 ECMO | 6 (5%) | 1 (1%) | 5 (12%) | < 0.05 |
 Vasopressor at any time | 86 (67%) | 50 (59%) | 34 (81%) | < 0.05 |
 RRT at any time | 24 (19%) | 13 (15%) | 13 (30%) | NS |
 ICU LOS | 16 [5–31] | 17 [5–31] | 15 [5–31] | NS |
Antiviral treatment | ||||
 None | 111 (86%) | 73 (85%) | 36 (86%) | NS |
 Immunoglobulin | 1 (1%) | 0 (0%) | 1 (2%) |  |
 Lopinavir-ritonavir | 5 (4%) | 4 (5%) | 1 (2%) | |
 Lopinavir-ritonavir + IFN-β | 2 (1%) | 0 (0%) | 2 (5%) |  |
 Hydroxychloroquine | 5 (4%) | 3 (4%) | 2 (5%) |  |
 Remdesivir | 5 (4%) | 5 (6%) | 0 (0%) |  |